Our overall project goal is to systematically link c/s-regulatory elements in pre-mRNAs to RNA structural features that control alternative pre-mRNA splicing in human cells. While the role of pre-mRNA structure in control of splicing events has been studied for individual genes, a comprehensive understanding of the interplay of RNA structure with splicing controland its relation to genetic variationis not known for the human transcriptome.
Our aims are to: 1) Map nuclear pre-mRNA structure in vivo and in vitro using high-throughput chemical probing methods and test the effects of RNA chaperone proteins on those structures. 2) Determine the positioning of mapped pre-mRNA structures relative to splicing factor binding sites, splice sites and exons, and human genetic variants. 3) Define a role for RNA chaperone proteins in alternative splicing decisions in human cells. 4) Develop and validate RNA maps relating RNA chaperone binding, RNA structure, and pre-mRNA splicing events, and validate roles of predicted structures in alternative splicing. These models will incorporate biochemical data, splicing reporter assays, as well as phylogenetic information and human genetic variation. Our efforts will initially focus on the genome-wide mapping of single-stranded RNA regions detected by chemical probing of pre-mRNA structure, as influenced by two known RNA chaperone proteins, the hnRNP protein hnRNPA1 and the p68/DDX5 RNA helicase. The RNA binding and chaperone activities (RNA annealing or unwinding) of hnRNP A1 and p68/DDX5 helicase will be correlated to global RNA structural data and alternative splicing patterns. We want to define instances where RNA structure plays a role in alternative splicing decisions and then integrate genome-wide data sets into these models. Our ultimate goal will be to generate systems level network models for how RNA structure and RNA chaperones, human genetic variation and histone marks, and RNA polymerase II distribution control alternative pre-mRNA splicing to inform both mechanistic aspects and the underlying molecular basis of human disease gene mutations.
|McGlincy, Nicholas J; Ingolia, Nicholas T (2017) Transcriptome-wide measurement of translation by ribosome profiling. Methods 126:112-129|
|Jost, Marco; Chen, Yuwen; Gilbert, Luke A et al. (2017) Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell 68:210-223.e6|
|Iwasaki, Shintaro; Ingolia, Nicholas T (2017) The Growing Toolbox for Protein Synthesis Studies. Trends Biochem Sci 42:612-624|
|Zubradt, Meghan; Gupta, Paromita; Persad, Sitara et al. (2017) DMS-MaPseq for genome-wide or targeted RNA structure probing in vivo. Nat Methods 14:75-82|
|Wright, Addison V; Liu, Jun-Jie; Knott, Gavin J et al. (2017) Structures of the CRISPR genome integration complex. Science 357:1113-1118|
|Lintner, Nathanael G; McClure, Kim F; Petersen, Donna et al. (2017) Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol 15:e2001882|
|Cate, Jamie H D (2017) Human eIF3: from 'blobology' to biological insight. Philos Trans R Soc Lond B Biol Sci 372:|
|Kostova, Kamena K; Hickey, Kelsey L; Osuna, Beatriz A et al. (2017) CAT-tailing as a fail-safe mechanism for efficient degradation of stalled nascent polypeptides. Science 357:414-417|
|Li, Bo; Tambe, Akshay; Aviran, Sharon et al. (2017) PROBer Provides a General Toolkit for Analyzing Sequencing-Based Toeprinting Assays. Cell Syst 4:568-574.e7|
|Liu, S John; Horlbeck, Max A; Cho, Seung Woo et al. (2017) CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355:|
Showing the most recent 10 out of 45 publications